Blar i Bergen Open Research Archive på forfatter "Luo, Tao"
-
Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer
Cheng, Bo; Ding, Kaikai; Chen, Pengxiang; Ji, Jianxiong; Luo, Tao; Guo, Xiaofan; Qiu, Wei; Ma, Chunhong; Meng, Xue; Wang, Jian; Yu, Jinming; Liu, Yuan (Journal article, 2022)Background Second-generation programmed cell death-protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors, such as bintrafusp alfa (M7824), SHR-1701, and YM101, have been developed to simultaneously block PD-1/PD-L1 ... -
PMEPA1 isoform a drives progression of glioblastoma by promoting protein degradation of the Hippo pathway kinase LATS1
Ji, Jianxiong; Ding, Kaikai; Luo, Tao; Xu, Ran; Zhang, Xin; Huang, Bin; Chen, An-Jing; Zhang, Di; Miletic, Hrvoje; Bjerkvig, Rolf; Thorsen, Frits; Wang, Jian; Li, Xingang (Peer reviewed; Journal article, 2019)The Hippo signaling pathway controls organ development and is also known, in cancer, to have a tumor suppressing role. Within the Hippo pathway, we here demonstrate, in human gliomas, a functional interaction of a transmembrane ... -
TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα
Ji, Jianxiong; Ding, Kaikai; Luo, Tao; Zhang, Xin; Chen, Anjing; Zhang, Di; Li, Gang; Thorsen, Frits; Huang, Bin; Li, Xingang; Wang, Jian (Journal article; Peer reviewed, 2021)NF-κB signaling plays a critical role in tumor growth and treatment resistance in GBM as in many other cancers. However, the molecular mechanisms underlying high, constitutive NF-κB activity in GBM remains to be elucidated. ...